Upstate Cancer Center joins key association
Based in Pittsburgh, AACI comprises 97 leading cancer research centers in North America. AACI’s membership roster includes National Cancer Institute-designated centers and academic-based cancer research programs that receive NCI support.
“Membership in this organization is another distinguishing feature of the Upstate Cancer Center as it recognizes our expertise in various areas, from our faculty, to our research to our patient care,” said Interim Director Jeffrey Bogart, MD, prorfessor and chair of the department of Radiation Oncology
The Association is dedicated to reducing the burden of cancer by enhancing the impact of North America’s leading academic cancer centers.
A key element of AACI’s mission is to assist the centers in keeping pace with the changing landscape in science, technology and health care. AACI does this by gathering and sharing best practices among cancer centers, providing a forum for members to address common challenges and explore new opportunities, supporting initiatives that engage the membership in developing specific recommendations to the NCI, and educating policy makers about the important role cancer centers play in advancing cancer discovery.
The Upstate Cancer Center sees more than 2,000 new cancer patients per year, resulting in 45,000 visits on its Downtown Campus and additional visits to satellite locations.
With an interdisciplinary cancer team that includes 90 board-certified physicians, all of whom are professors at the university’s College of Medicine, Upstate’s multidisciplinary programs include: breast cancer; gynecology oncology; head and neck; liver, gallbladder, and pancreatic cancer; neuro oncology; prostate cancer; thyroid cancer; and thoracic oncology.
Upstate is aiming for designation as a National Cancer Institute center. The effort involves clinicians, basic researchers, health care administrators and professionals, who are organized into several University-wide committees. Under a multi-year expansion plan, Upstate is committed to attracting and retaining staff to contribute to its translational research programs, including: tumor microenvironment and invasion; developmental cancer therapeutics; hematological malignancies; urological cancers; and, lifetime survivorship.